Erythromycin
产品说明书
 |
同义名 : | NSC 55929;E-Mycin;Eryc-250;Eryc-125;HSDB 3074 |
| CAS号 : | 114-07-8 | |
| 货号 : | A199997 | |
| 分子式 : | C37H67NO13 | |
| 纯度 : | 98% | |
| 分子量 : | 733.927 | |
| MDL号 : | MFCD00084654 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(143.07 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity[3]. Erythromycin inhibited growth of P. falciparum with IC50 and IC90 values of 58.2 ± 7.7 microM and 104.0 ± 10.8 microM, respectively. Combinations of chloroquine with erythromycin showed synergistic effects against parasite growth in vitro[4]. The most common side effect of erythromycin is gastrointestinal intolerance, which appears to be related to disruption of intestinal motility[5]. First generation derivatives such as 2'-esters and acid-addition salts significantly improved the chemical stability and oral bioavailability of erythromycin[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02757534 | Gastroparesis | Phase 2 | Enrolling by invitation | December 2020 | United States, Iowa ... 展开 >> University of Iowa Iowa City, Iowa, United States, 52242 收起 << |
| NCT01173133 | - | Unknown | December 2010 | United States, California ... 展开 >> Mills Penisula Hospital Recruiting Burlingame, California, United States, 94010-3282 Contact: John Griffin, MD 650-348-1503 Principal Investigator: John Griffin, MD 收起 << | |
| NCT01424254 | Gastrointestinal Bleeding | Phase 3 | Completed | - | Canada, Quebec ... 展开 >> Montreal General Hospital Montreal, Quebec, Canada, H3G1A4 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.36mL 0.27mL 0.14mL |
6.81mL 1.36mL 0.68mL |
13.63mL 2.73mL 1.36mL |
| 参考文献 |
|---|
|
[3]Brittain DC. Erythromycin. Med Clin North Am. 1987;71(6):1147–1154 |